✦ LIBER ✦

Risk stratification models and mutational analysis: Keys to optimising adjuvant therapy in patients with gastrointestinal stromal tumour

✍ Scribed by Gronchi, Alessandro

Book ID: 121775801
Publisher: Elsevier Science
Year: 2013
Tongue: English
Weight: 651 KB
Volume: 49
Category: Article
ISSN: 0959-8049
DOI: 10.1016/j.ejca.2012.10.025

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Cost-effectiveness of 3-year vs 1-year a

Cost-effectiveness of 3-year vs 1-year adjuvant therapy with imatinib in patients with high risk of gastrointestinal stromal tumour recurrence in the Netherlands; a modelling study alongside the SSGXVIII/AIO trial

✍ Majer, I. M.; Gelderblom, H.; van den Hout, W. B.; Gray, E.; Verheggen, B. G. 📂 Article 📅 2013 🏛 Informa plc 🌐 English ⚖ 336 KB

DEVELOPMENT OF PROGNOSTIC MODELS FOR IND

DEVELOPMENT OF PROGNOSTIC MODELS FOR INDIVIDUAL RISK STRATIFICATION IN PATIENTS TREATED WITH RADICAL NEPHROURETERECTOMY: A NEW TOOL TO HELP WITH PATIENT SELECTION FOR ADJUVANT THERAPY

✍ Shariat, Shahrokh F; Karakiewicz, Pierre I; Capitanio, Umberto; Raman, Jay D; Lo 📂 Article 📅 2009 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 128 KB

Tyrosine-kinase mutations in c-KIT and P

Tyrosine-kinase mutations in c-KIT and PDGFR-alpha genes of imatinib naïve adult patients with gastrointestinal stromal tumours (GISTs) of the stomach and small intestine: relation to tumour-biological risk-profile and long-term outcome

✍ Kjetil Søreide, Oddvar M. Sandvik, Jon Arne Søreide, Einar Gudlaugsson, Kjersti 📂 Article 📅 2012 🏛 Springer Milan 🌐 Spanish ⚖ 700 KB

Use of c-KIT/PDGFRA mutational analysis

Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group

✍ M. Debiec-Rychter; H. Dumez; I. Judson; B. Wasag; J. Verweij; M. Brown; S. Dimit 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 309 KB